D. E. Shaw & Co., Inc. Summit Therapeutics Inc. Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 29,779 shares of SMMT stock, worth $829,345. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,779
Previous 36,021
17.33%
Holding current value
$829,345
Previous $642,000
10.59%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding SMMT
# of Institutions
247Shares Held
87.4MCall Options Held
1.77MPut Options Held
2.48M-
Baker Bros. Advisors LP New York, NY24.4MShares$680 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$324 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$220 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$183 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$135 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.6B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...